drugset / Trial / NCT06916091

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

NCT06916091

Phase 1 Completed 30 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.

Timeline

Start
2025-04-21
Primary completion
2025-09-09
Completion
2025-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Eloralintide Protein / enzyme biologic Subcutaneous

Indications